BioCryst Pharmaceuticals, Inc. (BCRX) Misses Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $8.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
